Fair-Value Report — Sunshine Lake Pharma (6887.HK)

Insider Signal

Verified Snapshot

All financials in CNY (renminbi) as reported. FX: 1 CNY ≈ 1.091 HKD (implied from EPS cross-check). H shares = 321.1M post Full-Circulation (55.68% of total); Domestic = 255.6M (44.32% of 576.66M total). Financial data source: stockanalysis.com, HKEX filings (annual results announced 31 March 2026). Latest audited financials: FY2025 (December 2025 year-end, <8 months old). Data-recency guardrail: SATISFIED.

Business

Sunshine Lake Pharma (東陽光藥業) is a vertically-integrated Chinese pharmaceutical company founded in 2003 and headquartered in Dongguan, Guangdong. It develops, manufactures, and commercialises branded generic and innovative drugs across four therapeutic areas:

• Anti-infective: Kewei (oseltamivir phosphate) — ~27% of FY2025 revenue (CNY 1,301M); ~39% market share in China's anti-influenza segment. Seasonal demand profile; amplified by influenza outbreaks.
• Hepatitis C: Dongweien (emitasvir phosphate); direct-acting antiviral. Smaller but growing segment.
• Chronic Disease: Diabetes drugs; centralized procurement ("带量采购") exposure.
• Antibiotics / Anti-bacterial: Clarithromycin, Levofloxacin, Moxifloxacin.

Pipeline: 150 approved drugs (48 in China, 23 overseas); 100+ R&D candidates including 49 Class I innovative drugs. Three oncology candidates showcased at the 2026 AACR Annual Meeting. Management targets peak annual sales of RMB 20B (vs. RMB 4.8B today — an implied 4× uplift).

Geography: ~98% PRC; ~2% overseas (FY2025 data).

Valuation

Method: EV/EBITDA Scenario Analysis + P/E Sanity Check + Peer Table

Chosen method rationale: net income is volatile (swung from +CNY 1,993M in FY2023 to −CNY 207M in FY2024 to +CNY 272M in FY2025 due to oseltamivir seasonality), making standalone P/E unreliable. EV/EBITDA normalises better across the cycle. EBITDA is estimated at CNY 1,050M for FY2025 (EBIT CNY 691M + estimated D&A CNY 359M based on asset base). Net debt = CNY 4,680M − CNY 1,487M = CNY 3,193M.

Probability weights: Bear 25% / Base 50% / Bull 25%. The base case dominates. Bull case requires 43% EBITDA growth plus a premium re-rating — plausible if Class I drug launches materialise, but the history of volatile earnings warrants discounting.

P/E Sanity Check

At HKD 37.20 (4 Aug 2026), P/E TTM = 62.8×. For earnings to justify this on a normalised basis (target P/E 25×), net income would need to be ~HKD 892M (~CNY 818M) — roughly 3× FY2025's CNY 272M. That is achievable in a bull scenario but is not the base case. On base-case FY2027E net income of CNY 400M (a 47% improvement), fair P/E of 25× yields HKD 19 per share — below today's price.

Reverse Read

At HKD 37.20, the market implies ~22× EV/EBITDA on FY2025's EBITDA. For this to be "fair" on a 17× peer basis, EBITDA would need to grow to ~CNY 1,360M within 1–2 years (a 30% uplift from today). This is possible but not assured. The current price embeds above-base-case optimism.

Peer Comparison

Peer data sourced from PitchBook, CNBC, companiesmarketcap.com; estimates where exact FY2025 data unavailable. All data as of mid-2026. Sunshine Lake's P/E premium vs. CSPC (~63× vs. ~22×) is ~3× — requires sustained above-peer earnings growth to justify.

Conclusion

Sunshine Lake Pharma presents a genuine insider purchase signal: the controlling family's son (Zhang Yushuai, NED) bought ~HKD 49.25M of H shares on the open market on 31 July 2026. The signal is real; the question is whether it is sufficient to offset a stretched valuation.

Our conclusion is HOLD. The fundamental case is mixed:

• FOR: FY2025 recovery is real; +20% revenue growth; return to profitability from a loss position; oseltamivir franchise is durable; 49 Class I innovative drugs in pipeline represent optionality; H Share Full Circulation (May 2026) expands HK float and institutional visibility.
• AGAINST: Current P/E of 63× is ~3× the peer median; base-case fair value of HKD 27.7–31.8 is below the current price of HKD 37.20; high leverage (D/E 108%, net debt CNY 3.2B) constrains financial flexibility; earnings are volatile (3 out of 4 years below CNY 300M net income); the insider buy is only ~1.0% of Zhang's estimated H-share value — modest conviction signal; the stock has already fallen 8.5% since the purchase date, showing limited immediate market follow-through.

Upside path: If Class I drug approvals accelerate and oseltamivir maintains 2025 levels, earnings could reach CNY 700M+ by FY2027, justifying a re-rating to HKD 45–55. Downside path: If oseltamivir demand normalises to pre-2023 levels and leverage weighs on profitability, earnings could fall back below CNY 200M and the stock could de-rate to HKD 12–18.

The probability-weighted fair value is approximately HKD 32, implying ~14% downside to the current price. We do not see sufficient margin of safety to rate this a buy. Existing holders should monitor H1 2026 interim results (typically published August–September) for evidence of whether the recovery trajectory is holding.

Key Risks

• Oseltamivir concentration: ~27% of FY2025 revenue from a single, seasonally-sensitive product. A mild flu season or generic competition would disproportionately impact earnings.
• Leverage: D/E of 108%, net debt CNY 3.2B. Rising interest rates or earnings shortfall would stress debt serviceability.
• Earnings volatility: FY2022–FY2025 net income ranged from +CNY 1,993M to −CNY 207M. The current P/E embeds optimistic normalisation assumptions.
• VBP / Centralised procurement: Further price cuts via national volume-based procurement could compress margins on generic products.
• Pipeline execution risk: 49 Class I drugs are in various stages; clinical failure or regulatory delays would reduce the option premium embedded in the current price.
• Equity dilution risk: Book equity has fallen from CNY 7.9B (FY2023) to CNY 4.3B (FY2025), suggesting substantial dividend payouts or capital returns that may continue.
• H-share liquidity & post-Full-Circulation selling: 208.4M domestic shares converted to tradeable H shares in May 2026. Lock-up expiry for some converting shareholders could create near-term supply pressure.
• Small signal size: HKD 49.25M purchase is 0.22% of current market cap. Interpret as maintenance accumulation, not a decisive conviction bet.

Sources

• HKEX Filing — Sunshine Lake Pharma, "Issuance of Filing Notice by CSRC for H Share Full Circulation," 29 April 2026 (reviewed in full)
• HKEX News — Sunshine Lake Pharma Annual Results Announcement, 31 March 2026
• stockanalysis.com — 6887.HK Income Statement & Balance Sheet (accessed 4 Aug 2026)
• stockanalysis.com — 6887.HK Overview & Key Stats (price HKD 37.20, mkt cap HKD 22.14B, P/E 62.81, as of 4 Aug 2026)
• GuruFocus — Zhang Yushuai insider transactions page
• TradingView / Quartr — Sunshine Lake Pharma FY2025 results summary (revenue CNY 4.82B, net profit CNY 272M rebounded)
• companiesmarketcap.com / CNBC — CSPC Pharma (1093.HK) market cap and P/E as of mid-2026
• PitchBook — Sino Biopharmaceutical market cap / revenue data
• Simply Wall St — Balance sheet summary (D/E, equity, cash)
• MarketScreener / Minichart — H Share Full Circulation completion news